Popular Articles

BBC Examines River Blindness Program In Sub-Saharan Africa
BBC examines a campaign in sub-Saharan Africa that is helping to distribute drugs to prevent onchocerciasis, also known as river blindness - a disease "caused by a parasite that is spread from human to human by the black fly, which once flourished along river beds where there is fast-flowing water." According to the BBC, "Some 35 million people are currently infected with river blindness, and about 140 million people in Africa are at risk of infection."
generic viagra online
Landmark Study Published In New England Journal Of Medicine
One of the world"s most respected medical journals, the New England Journal of Medicine, is publishing a landmark study this week that explores treatments for people with both Type 2 diabetes and coronary artery disease. The Lang Research and Education Center of New York Hospital Queens was one of the sites that conducted this study.
News of the day
Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) For The Treatment Of Fabry Disease
Amicus Therapeutics (Nasdaq: FOLD) announced it has commenced the U.S. registration Phase 3 trial with its investigational drug, Amigal(TM) (migalastat hydrochloride) for the treatment of Fabry disease. The Company has reached agreement with the U.S. Food and Drug Administration (FDA) on the key protocol design elements of the pivotal trial, including the use of the surrogate primary endpoint of the change in the amount of kidney interstitial capillary GL-3, the substrate that accumulates in the cells of Fabry patients. In addition, the FDA is in agreement that the Company is eligible to seek Accelerated Approval for Amigal according to Subpart H regulations. The Company has begun submitting the Phase 3 protocol to investigational sites worldwide and expects to begin the dosing of subjects in the second half of this year.
Nutrition

ASHP, ASHP Foundation Launch Pharmacy Practice Model Initiative

The American Society of Health-System Pharmacists (ASHP) and the ASHP Foundation today announced the Pharmacy Practice Model Initiative (PPMI), the next major step in the evolution of pharmacy practice in hospitals and health systems. The PPMI will build on the landmark work of the Hilton Head conference, held by ASHP in 1985. The Hilton Head conference brought together a group of visionary pharmacists who helped establish the concept that the practice of pharmacy is a clinical profession and that the role of pharmacists in health systems should be focused on direct care of patients as part of multidisciplinary care teams. "Nearly 25 years after the Hilton Head conference, this vision has yet to be fully achieved," said ASHP President Kevin J. Colgan, M.A. "Pharmacy practice must continue to grow and evolve to reflect the advances in pharmacists" training and direct patient care roles, advances in technology, payer and regulator requirement, and demands for seamless care." A joint project of ASHP and the ASHP Foundation, the PPMI will be comprised of three components, including a summit to be held in 2010, a social marketing campaign to promote change, and demonstration projects. ASHP is currently seeking funding for these key activities. "Today"s environment makes this program critical for the future of the profession," said Colgan. "The pressures of an aging workforce and population, escalating costs, and health care provider shortages mean that health-system pharmacists must analyze and prepare for changes in the practice model that guides medication use in hospitals and health systems." ASHP"s Pharmacy Practice Model Initiative will: 1. Create a framework for a pharmacy practice model that ensures provision of safe, effective, efficient, accountable, and evidence-based care for all hospital/health system patients; 2. Determine patient care-related services that should be consistently provided by departments of pharmacy in hospitals and health systems and increase demand for pharmacy services by patients/caregivers, healthcare professionals, healthcare executives, and payers; 3. Identify the available technologies to support implementation of the practice model, and identify emerging technologies that could impact the practice model; 4. Support the optimal utilization and deployment of hospital and health-system pharmacy res through development of a template for a practice model which is operational, practical, and measurable; and 5. Identify specific actions pharmacy leaders and staff should take to implement practice model change including determination of the necessary staff (pharmacy leaders, pharmacists, and technicians) skills and competencies required to implement this model.) "This Initiative reflects a powerful movement from within our membership," notes Colgan. "The need for this Initiative kept surfacing in a variety of member groups within ASHP, including our policy-making Councils and our membership Sections, as well as during strategic planning for ASHP"s Leadership Agenda. Members are recognizing the need to take a holistic approach to redefining, reconstructing, and reinventing the practice model in light of technology advancements, the changing landscape of health care, and the growing patient care role of pharmacists." To learn more, visit http://www.ashp.org/ppmi. About ASHP For more than 60 years, ASHP has helped pharmacists who practice in hospitals and health systems improve medication use and enhance patient safety. The Society"s 35,000 members include pharmacists and pharmacy technicians who practice in inpatient, outpatient, home-care, and long-term-care settings, as well as pharmacy students. For more information about the wide array of ASHP activities and the many ways in which pharmacists help people make the best use of medicines, visit ASHP"s Web site, http://www.ashp.org, or its consumer Web site, http://www.SafeMedication.com. American Society of Health-System Pharmacists


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):